Taming the storm: potential anti-inflammatory compounds targeting SARS-CoV-2 MPro-Reference-Cited by-同舟云学术

Taming the storm: potential anti-inflammatory compounds targeting SARS-CoV-2 MPro

Published:2024-07-24 Issue: Volume: Page:
ISSN:0925-4692
Container-title:Inflammopharmacology
language:en
Short-container-title:Inflammopharmacol

Author:

Anton Débora Bublitz,de Lima Jeferson Camargo,Dahmer Bruno Rampanelli,Camini Ana Micaela,Goettert Marcia Inês,Timmers Luis Fernando Saraiva Macedo^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10787-024-01525-9.pdf

Reference199 articles.

1. Abdallah HM, El-halawany AM, Sirwi A et al (2021) Repurposing of some natural product isolates as SARS-COV-2 main protease inhibitors via in vitro cell free and cell-based antiviral assessments and molecular modeling approaches. Pharmaceuticals 14:213. https://doi.org/10.3390/ph14030213

2. Abian O, Ortega-Alarcon D, Jimenez-Alesanco A et al (2020) Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening. Int J Biol Macromol 164:1693–1703. https://doi.org/10.1016/j.ijbiomac.2020.07.235

3. Agarwal A, Hunt B, Stegemann M et al (2020) A living WHO guideline on drugs for covid-19. BMJ 370:m3379. https://doi.org/10.1136/bmj.m3379

4. Al-Ani B, Shamseldeen AM, Kamar SS et al (2022) Lipopolysaccharide induces acute lung injury and alveolar haemorrhage in association with the cytokine storm, coagulopathy and AT1R/JAK/STAT augmentation in a rat model that mimics moderate and severe Covid-19 pathology. Clin Exp Pharmacol Physiol 49:483–491. https://doi.org/10.1111/1440-1681.13620

5. Aldea M, Michot J, Danlos F et al (2021) Repurposing of anticancer drugs expands possibilities for antiviral and anti-inflammatory discovery in COVID-19. Cancer Discov 11:1336–1344. https://doi.org/10.1158/2159-8290.CD-21-0144